The vaccine and blood products supplier expects net profit for fiscal 2022/23 to range between $US2.4 billion and $US2.5 billion ($A3.4 billion and $A3.6 billion) - an increase of between 7.6 and 11.8 per cent over the past year.
"Fundamentally, the business is well positioned for growth post COVID with more collection capacity, more manufacturing capacity and good demand indicators," CEO Paul Perreault told analysts on Wednesday.
But he also warned supply chain challenges, inflationary pressures and higher plasma collection costs had all contributed to margin compression throughout the year.
CSL's Behring unit, the world's largest maker of blood plasma treatments, relies on paid donors in the United States for blood plasma which it converts to treatments for rare diseases.
The business, which contributes about three-quarters of the company's revenue, has experienced a slump in donations because of restrictions and health concerns since the onset of COVID-19 in 2020.
That supply disruption contributed to a six per cent drop in full-year net profit to $US2.26 billion ($A3.22 billion).
Plasma collections were impacted by the pandemic in FY21, constraining subsequent sales of core plasma therapies in FY22, given the long-term nature of our manufacturing cycle, the company said.
On a statutory basis, profit for the year to June 30 was down five per cent, on a constant currency basis.
Shares in the company dropped more than four per cent on the news, but recovered some of the losses in afternoon trading. By 1400 AEST on Wednesday, CSL shares were down 1.2 per cent to $292.74 each.
Mr Perreault expects the rebound in plasma collections seen during the second half of 2021/22 to bolster sales and profit growth of its core products - immunoglobulin and albumin - in the current financial year.
"Plasma collections have grown strongly - up 24 per cent over the previous year, which we anticipate will underpin strong sales growth this current financial year and we aim to continue this momentum into the future," he said.
Offsetting the weaker results, CSL reported a strong performance in its flu vaccines business Seqirus, with seasonal influenza vaccine sales jumping 16 per cent in the year with record volume of 135 million doses.
US vaccine sales topped $US1 billion for the first time.
That helped the company declare a partly-franked final dividend of $US1.18 per share, leaving the total dividend for the year steady at $US2.22 a share.
CSL's encouraging outlook excludes any contribution from the $US16 billion ($A23 billion) acquisition of Switzerland-based Vifor Pharma, which it completed earlier this month.
The company has previously indicated the deal will be immediately earnings per share accretive, and will help expand CSL's nephrology, cardiology and rare diseases product portfolio. It will hold a separate briefing to outline the combined guidance in October.
"Early data indicates no change to our overall view of the financial contribution from the acquisition of Vifor Pharma," Mr Perreault said.
"It remains a really good deal for CSL."
CSL SOLID FY RESULTS
* Net profit down 6 pct to $US2.26b ($A3.22 b)
* Total revenue up 2 pct to $US10.56 b ($A15.03 b)
* Final divided $US1.18 per share, partly franked
